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The central and peripheral nervous system are responsible for
sensing, encoding, and transmitting interoceptive and exteroceptive
information in order to output intricate biological processes, such
as learning, memory, and complex decision-making and the perfor-
mance of both reflexes and coordinated actions. To accomplish
such tasks, the primary units of the central and peripheral nervous
system, neurons, are organized into a circuit-based topography that
contains a diverse set of connections. In this context, neurons act as
nodes in these circuits and the connections between neurons as edges.
How neurons connect or “wire” together into these microscopic,
mesoscopic, and macroscopic circuits, as well as the function of these
assembled circuits, is of great interest to neuroscientists. Understand-
ing the topography and function of these circuits will aid neuroscien-
tists’ quest to elucidate where and how specific types of sensory,
motor, and cognitive data are processed to produce normal and aber-
rant biological processes. Yet, this task is tediously complicated, and
until recently, the tools needed to dependably perform such intricate
investigations were lacking. The introduction of the adeno-associated
viral vector (AAV) in neuroscience has helped advance both circuit
identification and functional circuit analysis, and the result has
dramatically expanded the capabilities of neuronal circuit character-
ization.1 AAVs have also been important tools for deciphering the
roles of specific gene products in neuronal function and animal
behavior. Furthermore, AAVs are increasingly promising clinical
tools for treating many neurological diseases and conditions. In this
review, we aim to briefly highlight AAV-specific technological devel-
opments, comment on their implications for neural circuit identifica-
tions, manipulations, and clinical utility, and discuss future capacities
for AAV-driven preclinical and clinical investigations. This review isMolecular Therapy: Methods
This is an open access article under the CC BY-NCnot intended as an exhaustive exploration of these topics, but rather as
a sampling of the myriad possible uses of AAVs for neuroscience
investigators.
AAVs
AAVs are small, 4.7-kb, linear, single-stranded DNA (ssDNA) viruses
in the parvovirus family that can infect multiple tissue types.2,3 The
AAV genome consists of two open reading frames, Cap and Rep,
which are flanked by inverted terminal repeats (ITRs).4,5 The ITRs
are the only elements of the AAV genome that must be delivered in
cis.6 Rep is translated to produce proteins necessary for AAV replica-
tion (Rep 40, 52, 68, and 78), while Cap is translated to produce
structural proteins VP1, VP2, and VP3 that form the 20- to 25-nm
icosahedral capsid at a ratio of 1:1:10.4,7 Cap also produces a non-
structural protein, assembly-activating protein, which is involved in
assembly of the capsid.7,8 The ITRs allow for the formation of a
hairpin structure, which permits primase-independent synthesis of
the second DNA strand via host cell DNA polymerase.5 Eleven natu-
ral serotypes of AAVs have been identified so far, which have different
capsid structures, resulting in differing tropism.7 AAV tropism can
also be further altered by creating recombinant versions of multiple
AAV serotypes, a process known as pseudotyping. These pseudo-
typed viruses can have enhanced tropism for specific cell types, as
well as improved transduction efficiency in neurons.9–13
To infect a cell, the AAV attaches to the cell membrane and undergoes
receptor-mediated endocytosis and endosomal trafficking.14 TheAAV
then escapes from a late endosome or lysosome and translocates to the
nucleus where the virus is uncoated. Double-stranded DNA is pro-
duced via the host cell’s polymerase.15 The fate of AAV then depends
on the presence of a helper virus, such as adenovirus or herpes simplex
virus. If no helper virus is present, AAV does not replicate. Most AAV
genomes remain in the nucleus as an episome in a latent state,
although a relatively small percentage may integrate into the host’s
genome assuming a latent state that does not engage the lysogenic
pathway.16 If a helper virus is present, AAV gene expression is& Clinical Development Vol. 17 June 2020 ª 2019 The Author(s). 69
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pressed, allowing for genome replication and progeny ssDNA particles
to be synthesized. The completed virions are assembled and released
from the host cell when the cell is killed through the lytic pathway
by the helper virus.3,17 AAV replication can also occur without the
presence of a helper virus if cellular stress is induced or if the helper
virus’s genes needed for AAV replication are provided in trans.18
AAVs integrate into a specific site in the human genome, AAVS1, on
chromosome 19, making AAV genomic insertions more predictable
than other viral vectors.19,20 Random integration into the host cell’s
genome does occur, but at a much lower frequency compared to other
vectors.21 However, the integrative capacity of AAVs can be prevented
by removing Rep and Cap from the AAV genome. To construct an
AAV transfer plasmid, the promoter and transgene are placed between
the two ITRs and Rep and Cap are supplied in trans for vector produc-
tion.22 In order for AAV replication to occur, an adenovirus, herpes
simplex virus, or a helper plasmid containing genes from adenovirus
is also required to mediate AAV replication.20,22
Among types of commonly used viruses in neuroscience, AAVs can,
similar to lentiviruses, infect both quiescent non-dividing cells, such
as neurons, as well as dividing cells, whereas retroviruses only infect
dividing cells. Additionally, AAV integration into the host genome
can be prevented by removing Rep and Cap genes from plasmids.22,23
When the recombinantAAV cannot integrate intoAAVS1, the virus is
processed into a double-stranded circular episome, which is main-
tained extrachromosomally and can persist in non-dividing cells for
years, allowing for long-term transgene expression in non-dividing
cells.23,24 This property makes them a prime candidate for neurosci-
ence research in that they are non-pathogenic, cause less immunoreac-
tivity than other viral vectors during and after transduction, can target
neurons without helper viruses or capsids, and have fewer effects on
basal cell function in comparison to other viral vectors.25–27 A draw-
back of AAVs is that they have relatively limited cloning capacity
and, therefore, large genes are not suitable for use in AAVs.28 When
an AAV exceeds its carrying capacity, the vector genome is truncated
during packaging at the 50 end. However, the use of dual or triple
AAVs can theoretically increase the packaging capacity via coinfection
of cells with partial sequence fragments. Partial sequence fragments are
joined through specific recombination sequences, such as the bacterio-
phage F1 AK sequence or portions of the ABCA4 gene, “double D”
format inverted terminal repeats, or by the utilization of intein-medi-
ated splicing to reconstruct full-length sequences, thus allowing for se-
quences larger than 5 kb to be delivered with AAVs.24,29–34 A final
disadvantage of AAVs is its ssDNA genome, since the virus relies on
the host cell’s replication machinery to synthesize the complementary
strand, which may delay transgene expression. Self-complementary
AAVs have been produced to circumvent the requirement of AAV
genome conversion to double-stranded DNA. Self-complementary
AAV vectors contain a packaged dimeric inverted repeat, allowing
the DNA to fold and base pair, forming double-stranded DNA. Self-
complementary AAVs allow for rapid transductions but have half
the cloning capacity of single-stranded AAVs.35–3770 Molecular Therapy: Methods & Clinical Development Vol. 17 June 20Preclinical Use of AAVs in Neuroscience Research
Circuit Identification and Classification
Neuronal circuits are currently defined by many factors, such as loca-
tion, connectivity, and cell type. Within a neural circuit, neurons that
originate from and terminate in the same location can be defined as a
node within a larger circuit. Within these nodes, subsets of neurons
that originate from and terminate to the same location may connect
to different cell populations at their origin or terminal end, further
differentiating the node by connectivity. Additionally, within simi-
larly connected nodes, some neurons may release different neuro-
transmitters (e.g., serotonin or glutamate), which can further
differentiate connected nodes by principal neuron type. Also, these
nodes may have morphological and electrophysiological differences
that can further specify the nodes by other cell-type attributes. A com-
bination of any or all of these factors may characterize a circuit node
while also differentiating it from a neighboring node. These differ-
ences may also be region-specific, as microcircuits can connect down-
stream to form larger circuits that regulate many complex cell and
biological outputs.
While this complexity presents many variables for neuroscientists to
grapple with during their investigations, a logical approach has been
to simplify larger circuits, focusing on characterizing specific nodes,
edges, and microcircuits within them. Findings from these experi-
ments can then be fed forward to define complex, larger circuits
through more multifaceted circuit manipulations and/or computa-
tional modeling. Thankfully, the unique properties of AAVs and their
ability to target specific nodes in neural circuits make them an excel-
lent choice for this paradigm.
To perform anatomical analyses of circuit nodes and comprehend
these circuit topographies, a common goal is to utilize a viral vector
that transduces a neuronal population of interest and expresses a fluo-
rescent protein to visualize the target. Given that host cells infected
with AAVs are unable to produce new viral particles, AAVs are there-
fore useful for infecting only one node of a larger circuit, as there is
little concern of the virus jumping across synapses to infect connected
neighbors. While low tropism and cellular transduction can be an
obstacle for using AAVs in rodents, recombinant AAVs (rAAVs)
have proven to be a useful solution for targeting specific neuronal
cell types and increasing transduction efficiency.38,39 Serotype 2
(AAV2) has a natural tropism for neurons and is the most commonly
used and characterized serotype.38 AAV2 vectors encoding fluores-
cent proteins have been instrumental in mapping connectivity be-
tween brain regions in animal models. For example, the Allen Mouse
Brain Connectivity Atlas project has utilized AAV2-EGFP vectors for
tracing the axonal connections between multiple brain regions in the
mouse brain.40 Many other laboratories also use similar techniques to
map numerous cell types and neurocircuits in not only mice, but in
many other species as well.
One disadvantage of AAV2 is that it is not able to be widely expressed
across all neuron types.38 This can prove difficult for infecting cells of
interest and, as a consequence, not all cells in the node would be20
Table 1. rAAV Serotype Family Properties
Serotype
Transport Direction Expression by Brain Region Cell-Type Expression
Anterograde Retrograde Striatum Hippocampus Cortex Neurons Astrocytes Microglia
rAAV1 + + * * * *** * **
rAAV2 + + * * * *
rAAV5 + *** *** * ** *
rAAV6  + * * ** **
rAAV7 + + ** ** *** ** ** **
rAAV9 + + ** * *** ***
The number of * represent relative rAAV expression levels by brain region or cell-type. * represents the lowest level of expression, ** represents general expression levels, and *** rep-
resents highest expression levels in comparison to other rAAV serotypes.
This table was developed with information based on the following citations: 26,161–166.
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this can be advantageous when the goal is to transduce a small num-
ber of neurons with minimal spread in a specific brain region.41 As
indicated above, currently 11 natural AAV serotypes have been iden-
tified, all with different natural tropisms and transduction properties.
Most AAV serotypes have the capability to transduce neurons, but
that strength of that transduction varies. Some serotypes exhibit dif-
ferential abilities to transduce neurons in vivo and in vitro. For
example, AAVs 1, 6, and 7 show the greatest specificity for neurons
over glia cells in culture, whereas in vivo following brain injections,
AAVs 1, 2, 5, 7, 8, and 9 all show strong preference for neurons in
many studies.41 As previously mentioned, one way to improve the
tropism of AAVs is to use pseudotyping. Pseudotyping involves engi-
neering new viral capsids from different serotypes to create rAAVs.
The most used examples are AAV2/5, which increase transduction ef-
ficiency and tropism for neurons by combining specific parts of the
capsid and genome of AAV2 and AAV5.42 Also, AAV-DJ, a hybrid
of eight capsid types, and AAV-DJ8, a revision of AAV-DJ, have
been used to increase transduction rates in vitro and in vivo, respec-
tively.43 A table for natural and recombinant AAV characteristics has
been included for quick reference (Table 1).
rAAVs also aid in physical targeting and provide increased infection
strategies. Most AAVs display the ability to be anterogradely trans-
ported. For example, AAVs can be placed at or near the cell body,
transported into the cell, and then translocated into the nucleus for
transduction as well as anterogradely down the axon to the nerve ter-
minals (Figure 1A). Yet, some AAVs display the natural ability to be
transported retrogradely and thus can be transported into the nerve
terminal, transported retrogradely down the axon, and translocated
into the nucleus for transduction (Figure 1B). However, most
AAVs facilitate retrograde transduction poorly. The property of
anterograde, retrograde, and bidirectional transport is also serotype-
and concentration-dependent.44 One initial solution to increase
retrograde transportation was to use AAVs that that utilize specific
promoters, such as AAV-CAV, that recognize receptors on axon ter-
minals to increase tropism and efficiency. New iterations of rAAVs,
such as rAAV2-retro, have improved retrograde transduction effi-
ciency and tropism for a variety of neuron types via an engineeredMolecupeptide insertion between amino acid 587 and 588 in the AAV2
BP1 capsid gene, and they allow more packaging capacity for specific
promoter-driven sequences to be used for higher cell-type specificity
during transduction.45,46 However, some AAV serotypes (AAV1,
AAV9) are capable of migrating trans-synaptically, allowing for
transduction to cross synapses for circuit network labeling and
manipulation (Figure 1C).47 These tools aid researchers aspiring to
anatomically describe circuits by providing them with a multitude
of options for viral placement and provide confidence that their
node of interest will be targeted and transduced by the vectors.
New technological developments in rAAVs are always ongoing. For
example, a new generation of rAAVs have introduced a new delivery
system for targeting AAVs to neurons in the central and peripheral
nervous system. AAV-PHP.eB and AAV-PHP.S can target neurons
in the CNS and PNS, respectively, when injected intravenously,
bypassing the need to perform site-directed injections in the
brain,23,48,49 but also see Foust et al.27 This approach decreases exper-
imental complexity for research paradigms and also opens new ave-
nues to targeting neurons for therapeutic gene delivery both in rodent
and human models. Also, new AAV variants that rely on transcrip-
tional targeting such as AAV5- glial fibrillary acidic protein
(GFAP)/GfaABC1D and AAV6-scCBA, a hybrid chicken b-actin
(hCBA) promoter fused to rAAV6, have been identified to preferen-
tially physically target other cells in the central nervous system, such
as astrocytes andmicroglia, respectively.50,51 Not only can researchers
perform anatomical circuit analysis with rAAVs, taking advantage of
both anterograde and retrograde transport in neurons, but also the
increasing diversity of injection strategies and the ability to directly
(e.g., neurons) and indirectly (e.g., astrocytes and microglia) label cir-
cuit nodes are now accessible for experimental designs.
rAAVs display outstanding tropism and transduction efficiency for
neurons, but AAVs and rAAVs also provide an improved method
for infecting specific neuronal cell types using intersectional genetics
approaches. rAAVs can be used to not only target specific nodes
within a circuit, but also to infect cells only expressing a specific ge-
netic marker, thus targeting specific cell populations via what tran-
scripts those populations express. This approach allows AAVs tolar Therapy: Methods & Clinical Development Vol. 17 June 2020 71
Figure 1. Physical Targeting of Neuronal Populations
(A) Anterograde transport methodology: AAV vector infusion results in transduction within cell bodies localized proximal to the injection target. Dependent on vector con-
struction, subsequent cellular trafficking may result in the spread of the transgene product throughout neuronal somatodendritic compartments as well as anterograde
transport along axons. This methodology may be useful for mapping neuronal projections, manipulating multiple projection targets through targeting of the cell bodies of
transduced neurons at the injection site, or manipulating specific projection targets by targeting axon terminal fields. (B) Retrograde transport methodology: AAV vector
infusion results in uptake within axon terminals at the injection site and retrograde transport from the terminals to the nucleus with subsequent transduction and expression of
transgene. This methodology may be useful for determining neuronal connectivity as a complementary role to the anterograde methodology. (C) Trans-synaptic transport
methodology: specific AAV vectors (e.g., AAV1 or AAV9) are used as described for anterograde transport methodology, but following transport to terminals they are able to
migrate trans-synaptically to synaptically connected target neurons. This is especially useful for mapping of and manipulation of neurocircuits, rather than just neuronal
connectivity.
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as a Boolean function for the virus to enter specific cell types and
avoid others. To accomplish this task, AAV genomes can be modified
to only be transduced in cells that express like promoters (Figure 2A)
(e.g., Ca2+/calmodulin-dependent protein kinase II alpha [CamKIIa],
superoxide dismutase-2 [SOD2], GFAP).52–54 Furthermore, AAVs
can be modified to control expression using Cre or Flp to drive
recombination events, thus regulating transduction by viral recombi-
nation. By inserting a double-floxed inverse orientation (DIO)
element, a molecular switch that utilizes flanking loxP recognition
sites, into the AAV genome, gene expression can be driven by Cre
and Flp recombinases to only express genes of interest in cells that
also express Cre or Flp.55 Additional information on Cre-loxP sys-
tems are reviewed elsewhere.56 This allows neuroscientists to combine
AAV-DIO viruses with mouse lines that express Cre in specific cell
types to drive transduction in circuits across the brain. A second op-
tion is to use a second AAV virus driven by a promoter that encodes72 Molecular Therapy: Methods & Clinical Development Vol. 17 June 20Cre or Flp in combination with an AAV-DIO to isolate the transduc-
tion of the viral genome to highly specific cell populations within pre-
cise locations of circuits of interest (Figure 2B).55,57,58 For example,
Guo et al.59 combined many of the above techniques to map whole-
brain inputs into the dorsal striatum. By injecting two AAV-DIO vec-
tors (AAV-DIO-EGFP-TVA and AAV-DIO-RG) under a CAG pro-
moter into choline acetyltransferase (ChAT)-Cre, D1-Cre, and D2-
Cre mice in the dorsal striatum, the group was able to transfect
only neurons that project to and are within the dorsal striatum
with a fluorescent reporter and two of the three necessary products
for transsynaptic rabies labeling. Two weeks later, a modified rabies
virus was injected that only infected cells that were previously trans-
duced with the earlier AAV injection. This approach allows for label-
ing of the input neurons into the dorsal striatum across the brain by
utilizing two promoter-driven AAV-DIO vectors, transsynaptic
retrograde labeling techniques, as well as local anterograde labeling,
and it utilizes a modified rabies virus. Thus, many of these20
Figure 2. Transcriptional Targeting of Neuronal Populations
(A) AAV vector expression may be restricted to specific neuronal populations by using AAV vectors constructed with a cell type-specific promoter. In this example, the AAV
vector encodes a GFP under the control of the Ca2+/calmodulin-dependent protein kinase II alpha (CaMKIIa) promoter. Cellular transduction will only result in transgene
expression in neurons expressing CaMKIIa. (B) AAV vector expression may be restricted to specific neuronal populations using transgenic mice expressing cre-recombinase
within specific cell types. AAV vectors are constructed to be dependent on the activity of cre-recombinase. In this example, using a “Cre-on” strategy, an AAV vector has a
GFP-encoding sequence in a double-floxed inverse orientation (DIO). It is infused into transgenic mice that express cre-recombinase within choline acetyltransferase-ex-
pressing cells (ChAT-Cre mice). Upon cre-recombinase-mediated recombination, the GFP sequence is flipped into a sense orientation allowing for expression of GFP only in
cells that express ChAT. Alternatively, AAV vectors may utilize a “Cre-off” strategy under which cre-recombinase-mediated recombination flips a transgene’s sense
orientation, resulting in a lack of vector expression only in cells that express cre-recombinase.
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neuroscience research.
Circuit Manipulation
Not only are AAVs an extremely flexible, efficient, and reliable tool
for transducing reporters into specific nodes of circuits to understand
the topography of neural circuits, but the ability to package elements
into them beyond fluorescent reporters is truly where they have revo-
lutionized neuroscience research. While the packaging capacity is
relatively limited in AAVs, around 4.8 kb in size, the ability to encode
a vast variety of proteins that canmodulate circuit nodes has provided
the ability to temporally control neuronal function with extremely
tight control and accuracy in real time. Most notably, optogenetic
and chemogenetic tools have revolutionized the ability to manipulate
specific nodes, edges, and microcircuits. Optogenetics involvesMolecuplacing the sequence for a light-inducible excitatory (e.g., Channelr-
hodopsin2, ChrimsonR, etc.) or inhibitory (e.g., Arch, eNpHR, etc.)
ion channel within the AAV vector.60–63 This allows for the insertion
of these channels into the membrane after viral vector transduction
that provides the investigator with the ability to alter specific neuronal
properties using specific wavelengths of light with extreme temporal
precision. Activation of these light-driven channels alters membrane
potential dynamics and neurotransmitter release. This provides neu-
roscientists with the ability to use different wavelengths of light to
modulate neuronal firing on microsecond timescales by either
increasing or decreasing firing of neurons within nodes of interest.
Alternatively, light can be used to manipulate presynaptic excitability,
allowing investigators to probe inputs from one node into another.
This application provides the ability to probe effects of circuit modu-
lation in in vitro, ex vivo, and in vivo models. The power of in vivolar Therapy: Methods & Clinical Development Vol. 17 June 2020 73
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late behaviors such as altering taste perception in real time to chang-
ing positive and negative memory association.64,65 Chemogenetic
tools, such as DREADDs (designer receptors exclusively activated
by designer drugs) can be used similarly to optogenetic tools packaged
in AAVs, but these vectors encode engineered G protein-coupled re-
ceptors that bind inert chemicals such as clozapine-n-oxide or salvi-
norin B.66,67 Excitatory and inhibitory DREADDs also allow for con-
trol over neuronal function; however, chemogenetics works at greater
timescales in comparison to optogenetic techniques, at the minute to
hour timescale. For example, Krashes et al.68 targeted an excitatory
DREADD to a specific set of neurons that are important in regulating
feeding using an AAV-DIO and Cre-AgRP mouse line. When stimu-
lating the DREADD receptors to activate the neurons that they were
expressed on, the group was able to show that food intake increased
for up to 24 h after activating the DREADD receptors. This displays
the power of long-term modulatory effects that are achievable via
chemogenetic techniques not only for feeding. When paired together,
optogenetic and chemogenetic tools can offer interesting insights into
how manipulating specific nodes within neural circuits leads to
changes in neuronal function, synaptic plasticity, and ultimately com-
plex biological behaviors.
Beyond directly manipulating nodes, packing calcium, neurotrans-
mitter, and voltage-sensitive fluorescent reporters into AAVs has
given neuroscientists the ability to sample neuronal firing in
ex vivo and in vivo models. The Looger lab has developed calcium-
sensitive proteins that contain a fluorescence molecule integrated
with calmodulin that changes its fluorescent activity when calcium
is released in the cell.69 Considering that calcium is an important sec-
ondary messenger in many signal cascades and is dynamically and
rapidly released during neuronal activation, these sensors act as
proxies for neuronal activity that are visible using light capturing de-
vices such as optic ferrules paired with high-powered microscopes,
such as two-photon and stimulated emission depletion (STED) mi-
croscopes. This allows researchers to specifically express these sen-
sors in neurons of interest to study node activity in freely behaving
rodents and non-human primates or modulate some other input of
the circuit using optogenetics or chemogenetics and image the
output at some other location in the node. Studies using these
approaches made possible by AAVs can decipher true measures of
input/output changes within circuits. By using such techniques, in-
vestigators are able to view real-time calcium imaging data that
demonstrate how dopamine neurons contribute to reward, reward
prediction errors, aversion, and skill-learning tasks.70,71 Also, moni-
toring ventral tegmental area (VTA) dopaminergic neurons has
allowed for mathematical models of how different inputs, such
as motor, sensory, and cognitive variables modulate dopamine
release.72 Beyond calcium, there are now available sensors for gluta-
mate (iGluSnFR), g-aminobutyric acid (GABA) (iGABASnFR),
dopamine (dLight), and many more currently under develop-
ment.73–76 AAV-driven genetically-encoded fluorescent voltage sen-
sors allow for direct visualization of membrane voltage dynamics
within AAV-transduced neurons.77 Not only can neuroscientists74 Molecular Therapy: Methods & Clinical Development Vol. 17 June 20now visualize neuronal firing changes, they can also determine the
contents released from these nodes and how diversity in these signals
can modulate specific circuits.
AAVs have also been useful tools for “tagging” neurons. Tagging
techniques are useful for identifying recorded neurons in vivo, assess-
ing neuronal network activation following completion of behavioral
sequences or a specific in vivo treatment, or for post hoc isolation of
activated cells for genetic or proteomic analyses.78,79 For example,
channelrhodopsin-2 (ChR2) can be packaged within an AAV in con-
cert with a separate transduction of herpes simplex virus 1 (HSV1) to
transduce a specific subset of neurons. The output is a grouping of
neurons that are labeled with HSV1, ChR2, or both. Upon a quick
pulse of light, the subpopulation of ChR2-targeted neurons can be
illumined to determine their location versus unlabeled neurons.
Further functional comparisons in vivo can then be achieved such
as functional activity assessments of ChR2-labeled subpopulations
or microcircuit analysis of the connectivity between large populations
of neurons.80,81 Tagging activated cells that respond to complex
biological behaviors, such as memory, is also achievable with
AAVs. Using FosTrap, a dual-virus approach that utilizes an AAV
with a molecular tag or substrate and a separate AAV-cFos, allows
for the molecular tag to be transduced in neurons that were only
recently functionally active. cFos, an intermediate early gene, is ex-
pressed within a cell upon neuronal activation, which then allows
the second AAV carrying a reporter gene or molecular substrate to
be transduced only in those activated cells. This tool has allowed re-
searchers to tag and trace engram cells, which are cells that encode
contextual memory. Such experiments have allowed for modulation
of molecular substrates via optogenetic and chemogenetic techniques
that underlie fear memories. In essence, researchers can effectively
silence or enhance specific contextual memories at the cell level.
This has in turn advanced our understanding of where and how
specific memories are formed in the brain and also helped further
the understanding of themolecular and circuit basis of post-traumatic
stress disorder and other anxiety-related disorders.82,83
Other AAV Functions
Beyond manipulating neuronal firing and sampling neuronal activity,
AAV vectors have provided alternative ways to alter circuit nodes.
AAV-CASP3 is a cell death protein transduced by an AAV that allows
specific ablations of neuronal populations of interest.84 This approach
iterates on classical pharmacological or mechanical lesion studies to
provide advanced targeting when aiming to remove specific connec-
tions in a node while decreasing off-target effects. AAVs have been
incredibly useful tools for exploring the role of specific gene products
within specific cell types within specific nodes in neuronal function
and behavior. This can be accomplished by AAV-driven cre-recom-
binase expression within defined brain regions using cell type-selec-
tive promoters in mice that are conditional knockouts for proteins
of interest or in mice transduced with other cre-recombinase-depen-
dent vectors.85–87 Also, mechanistic changes downstream of neuronal
activation or silencing are now achievable with AAVs that can control
endosome trafficking via light, which allows for general control of20
Table 2. Summary of Disease Indications for Which AAV-Based Gene
Therapies Have Been Applied in Clinical Trials Worldwide
Inborn errors of metabolism Neurologic
 Lipoprotein lipase deficiency
 Canavan disease
 Batten disease
 Mucopolysaccharidosis type I, II, IIIA,
IIIB, and VI
 Metachromatic leukodystrophy
 Aromatic L-amino acid decarboxylase
deficiency
 Familial hypercholesterolemia
 Acute intermittent porphyria
 Crigler-Najjar syndrome
 Tay-Sachs disease
 Pompe disease
 Galactosialidosis
 Ornithine transcarbamylase deficiency
 Glycogen Storage Disease Type I
 Parkinson’s disease
 Alzheimer’s disease
 Spinal muscular atrophy
 Amyotrophic lateral sclerosis
 Temporal lobe epilepsy
 Charcot-Marie-Tooth neuropathy type
1A
Ocular
 Leber congenital amaurosis
 Leber hereditary optic neuropathy
 Choroideremia
 Age-related macular degeneration
 Achromatopsia (Color Blindness)
 Retinitis pigmentosa
 X-linked retinoschisis
Musculoskeletal Cancer related
 Rheumatoid arthritis
 Osteoarthritis
 Muscular dystrophies (Duchenne,
Becker, and Limb-Girdle)
 Digital flexor tendon injury
 Gastric cancer
 Prostate cancer
 Nasopharyngeal carcinoma
 Multiple myeloma
 Malignant melanoma
 Non-Hodgkin lymphoma and B cell
acute lymphoblastic leukemia
 Irradiation-induced parotid salivary
hypofunction
Pulmonary
 Cystic fibrosis
Cardiovascular
 Chronic heart railure Hematologic
Infectious  Hemophilia A and B
 HIV
 Hepatitis C
Multisystem
 Alpha-1 antitrypsin deficiency
 Prader-Willi syndrome
This table was developed based on the information provided by Gene Therapy Clinical
Trials Worldwide, The Journal of Gene Medicine (http://www.abedia.com/wiley/index.
html).
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adhesion molecules at specific sites.88 Also, recently the machinery
required for CRISPR, the directed gene editing technique, have
been packaged into AAVs to perform site-specific gene editing in
neurons of interest to perform gain- or loss-of-function mutations
as well as gene editing in real time to determine the effects of genetic
alteration on circuit function.89–91
Clinical Use of AAVS
The search for the perfect gene-carrying vector has been underway
from the moment gene therapy was first hypothesized to be a poten-
tial treatment for disease. An ideal gene-carrying vector must have a
high rate of gene transfer, produce long-term gene expression, and
possess low immunogenicity and pathogenicity to be a successful
candidate for therapy.92,93 Replication-defective retroviruses were
the original vectors used during the earlier stages of gene therapy;
however, the potential genotoxicity resulting from integration into
the host’s genome raised concerns that impeded advancements.94
However, the second wave of gene therapy in the early 2000s was
marked by the rising use of AAVs.94 AAVs largely meet all character-Molecuistics required of a successful gene vector. Although complex immune
responses directed against AAV vector-based gene therapies are
known to occur, overall, AAVs maintain an impressive safety and
tolerability profile.93,95 Additionally, AAVs efficiently transduce
both non-dividing and dividing cell types for a clinically relevant
length of time in many cases.96 Although AAV2 is the most widely
used variant because it was the first serotype identified, numerous
other serotypes with varying tropism exist, giving AAVs wide clinical
applicability.92,93,97 When combined, these characteristics have estab-
lished AAVs as a leading vector choice for gene therapy studies with
one of the highest margins of success.98
Although AAV-based gene therapies have grown rapidly, the use of
this vector is still associated with some challenges. For systemic
administration of AAV-based gene therapies, the ability to target spe-
cific cell types and pass through barriers (e.g., the blood-brain barrier)
to those tissues is particularly challenging.99 Additionally, most of the
population has been naturally exposed to many AAV serotypes,
resulting in neutralizing anti-capsid antibodies.99–102 Both challenges
can significantly reduce the transduction efficiency of AAVs.
However, some innovative strategies, such as rationally designed
AAV variants through site-directed mutagenesis and directed evolu-
tion, are being employed to aid in vector improvement and circum-
vent these barriers to therapeutic success.23,99,103–105 The packaging
capacity of AAVs can also be a challenge for certain gene thera-
pies.93,101 Coding sequences larger than 5 kb are unlikely to be effec-
tively packaged into the vector or successfully transduced.93,97 While
this size limitation is rarely a concern for human therapeutic applica-
tions, overlapping dual or triple AAV vectors are a possible solution
for expressing genes that exceed the packaging capacity of AAVs.33,97
For example, a dual AAV approach was successfully used to restore
expression of otoferlin, a protein whose coding sequence exceeds
the packaging capacity of a single AAV, in the cochlea of otoferlin
null mice, a mouse model of genetic human deafness.106 A triple
AAV approach improved the capacity to 14 kb and allowed investiga-
tors to express the ciliary/centrosomal protein, ALMS1, which has a
cDNA length of 12.5 kb, in mouse and pig retina.33 Transduction ef-
ficiency in mice was very low, but achieved 40% transduction in pigs.
The low expression in mice may be explained by species differences,
but this will require additional study. Studies such as these provide
promise for more flexible gene therapies in the future. As advance-
ments in AAV virology and engineering continue, a growing reper-
toire of AAV variants with high tissue specificity and transduction
efficiency will continue to become available for clinical studies.
AAVs have been utilized in more than 230 active or completed
clinical trials worldwide.101,107 See Table 2 for many of the clinical
indications where AAVs were used as vectors in clinical studies. Addi-
tionally, the viral vector was among the first ever approved gene ther-
apy in the form of Glybera, approved by the European Medicines
Agency in 2012 for the treatment of lipoprotein lipase deficiency
(LPLD), and also Luxturna, approved in 2017 by the US Food and
Drug Administration (FDA) for a rare type of retinal dystro-
phy.97,99,108 Although a full description of all clinical studies is notlar Therapy: Methods & Clinical Development Vol. 17 June 2020 75
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ical applications for AAVs is included below.
Approved Applications of AAV-Based Gene Therapies
LPLD is a rare genetic disease resulting in chylomicronemia and hyper-
triglyceridemia, which can put individuals at risk for pancreatitis and
pancreatic insufficiency.109 After promising preclinical data, the first
human trial for an AAV vector to deliver a gain-of-function lipopro-
tein lipase gene variant began in 2005 in Europe.110 In addition to
being well tolerated, half of the subjects had aR40% reduction in tri-
glycerides 12 weeks following vector administration.110 Two additional
clinical trials using the same AAV vector, now referred to as alipogene
tiparvovec (Glybera), similarly demonstrated that the gene therapy
product decreased plasma triglycerides transiently, positively altered
chylomicron metabolism, and led to persistent expression of the func-
tional lipoprotein lipase enzyme.111,112 After a final retrospective anal-
ysis demonstrating that the product was able to reduce the risk of
pancreatitis in LPLD, Glybera became the first gene therapy approved
in Western world.113 Unfortunately, 5 years after this approval, the
maker of Glybera announced it would withdraw the therapy due to
the exceptionally high cost of treatment.114
Due to the immune privilege of the eye, the localized anatomy within
a closed physical space, and post-mitotic state of retinal cells, AAV-
based gene therapies for inherited retinal diseases have been
extensively tested.94,115 Luxturna (voretigene neparvovec) delivers a
functional RPE65 gene that encodes an enzyme crucial to the retinoid
cycle in patients with Leber congenital amaurosis, a rare, blinding
retinal dystrophy.94,101,116 In clinical trials, this AAV2-mediated ther-
apy improved light sensitivity, navigational abilities, and visual acuity
in those with the condition.116,117
Spinal muscular atrophy (SMA), the most common genetic cause of
death in infants, results from a loss or dysfunction in the survival motor
neuron (SMN1) gene.118 The disease results in progressive loss of lower
motor neurons and muscle atrophy, often leading to respiratory fail-
ure.118 An intravenous AAV9-SMN approach was able to rescue motor
neurons, leading to a significant prolongation of lifespan in a mouse
model of SMA.119 This same method was replicated in a small clinical
study of 15 infants with SMA beginning in 2014. All patients who
received either the low or high dose of the systemically administered
AAV9-SMN vector were alive at 20 months of age compared to an 8%
survival rate at this time in a historical cohort.118 Many of these infants
were able to achieve clinically meaningful motor developmental mile-
stones such as feeding, sitting, and talking, which is typically not present
in historical cohorts.118While a larger global clinical trial is still ongoing
(ClinicalTrials.gov: NCT03505099), in May of 2019, the FDA approved
Zolgensma (onasemnogene abeparvovec-xioi; an AAV9-SMN vector)
for the treatment of SMA in children less than 2 years of age.
Potential Central Nervous System Applications of AAV-Based
Gene Therapies
As the blood-brain barrier prevents many systemically administered
drugs from reaching the central nervous system and direct intrapar-76 Molecular Therapy: Methods & Clinical Development Vol. 17 June 20enchymal delivery of therapeutics would require frequent re-admin-
istration, gene therapy for neurological diseases is an attractive
treatment modality.120,121 To date, nearly all gene therapy clinical
trials of neurological diseases have utilized AAVs as vectors for deliv-
ery.121,122 Much of the promising results in these gene therapy trials
have been observed in studies of choroideremia, Parkinson’s disease
(PD), and Alzheimer’s disease (AD).
Another AAV-based gene therapy is projected to be approved for the
treatment of choroideremia, a progressive X-linked recessive blinding
condition due to mutations in the CHM gene.101,123,124 Using an
AAV2 vector, a functional CHM gene delivered into the retina of
one eye significantly improved visual acuity compared to the control
eye, which did not receive the functional gene. Impressively, this
improvement in visual acuity remained for 3.5 years post-treatment
in two out of the six patients despite progressive degeneration in
the control eye that did not receive intervention.124,125
In PD trials, AAV-transduced genes are frequently neurotrophic fac-
tors to potentially prevent cell death or enzymes related to neuro-
transmitter synthesis that may modulate neuronal activity.104 One
frequently studied method involves AAV-mediated delivery of
aromatic L-amino acid decarboxylase (AADC), the final enzymatic
step that converts levodopa into dopamine, into the striatum. Levo-
dopa therapy often fails to alleviate motor symptoms, as the PD
progresses even with increasing doses, but AAV-AADC gene therapy
replacement may offer a strategy to maintain steady dopamine con-
centrations in patients taking levodopa.121 Early-phase studies
demonstrated successful gene expression and moderate improve-
ments in motor symptoms when an AAV-AADC was delivered to
the putamen bilaterally, but larger controlled trials are necessary to
accurately assess the efficacy of the treatment on disease symptomol-
ogy over time.126,127 Two additional phase I trials are underway using
a real-time MRI-guided approach to monitor delivery of an AAV2-
AADC with the goal to more accurately target the putamen (Clinical-
Trials.gov: NCT01973543 and NCT03065192). An alternative
GABAergic approach delivers the glutamic acid decarboxylase gene
(the rate-limiting enzyme in GABA synthesis) to the subthalamic
nuclei of patients. Phase I and II studies in patients with PD reported
that the vector was well tolerated and mildly improved motor symp-
toms up to 6 months following gene transfer, suggesting it may be a
promising treatment modality for the disease.128,129 Intraparenchy-
mal administration of AAV vectors also has the potential to persis-
tently express genes that target the progressive accumulation of
abnormal proteins that characterizes many neurodegenerative dis-
eases, including PD.121 Another AAV-based gene therapy approach
involves the expression trophic factors such as glial-derived neuro-
tropic factor (GDNF) or neurturin, a structural and functional analog
of GDNF.121 The delivery of GDNF or neurturin into the putamen
have shown promise as neuroprotective agents in rodent and
nonhuman primate phase I clinical studies of PD.121,126,127,130–133
However, two larger, double-blinded randomized trials failed to
show that an AAV2-neurturin gene therapy injected bilaterally into
the putamen and the putamen and substantia nigra were superior20
www.moleculartherapy.org
Reviewto sham surgery.130,134 Although an additional phase I, open-label
trial using AAV2-GDNF delivery to the putamen is underway (Clin-
icalTrials.gov: NCT01621581), the previous larger, double-blinded
trials certainly cast doubts on the future of trophic factor gene therapy
in PD; however, larger viral infusion volumes and more accurate de-
livery guided by real-time MRI may offer some hope.121,122,135
Neurotrophic factors have also been explored in the treatment of AD.
Nerve growth factor (NGF) is one such neurotrophic factor that has
been shown to promote neurorestoration and neurorepair of cholin-
ergic neurons of the basal forebrain.136,137 Dysfunction of this
neuronal population is thought to underlie the clinical symptomology
of AD, and cholinesterase inhibitors, a mainstay of disease treatment,
are known to exert their therapeutic effects on the basal forebrain
cholinergic neurons.138,139 While an initial gene therapy trial of
NGF utilized an ex vivo approach, subsequent human studies
employed an in vivo AAV2-based strategy to deliver the NGF
gene.139–142 AAV2-NGF delivered to the nucleus basalis of patients
with AD is well tolerated and leads to persistent expression of NGF
up to 4 years after treatment.142 Upon autopsy in two patients, the
neurons of the nucleus basalis displayed signs of a trophic response
(e.g., axonal sprouting toward NGF and increased cellular signaling
molecules).140 Unfortunately, in a sham surgery-controlled trial of
49 patients with AD, AAV2-NGF had no benefit over placebo on
cognitive measures 24 months post-injection.139 As with other neuro-
logical gene therapy trials, the authors suggested that vector mistar-
geting could underlie the lack of successful findings for NGF in the
treatment of AD. Other gene-based strategies for treating the disease
include the transduction of APOE, a regulator of lipid metabolism in
the brain that has been shown to alter the handling of b-amyloid. The
APOE2 allele has been shown to be protective in AD, likely by
decreasing plaque burden.143 In pursuit of this protective effect, an
ongoing phase I trial is investigating the effects of AAV-APOE2 trans-
duction in patients who are homozygote for APOE4, the allelic form
of the lipid regulator associated with AD (ClinicalTrials.gov:
NCT03634007).
AAV-based gene therapies are quickly becoming a popular investiga-
tive treatment strategy for many other neurological conditions in
animal models. Promising preclinical studies employing AAVs have
also been completed in models of Huntington’s disease (HD), amyo-
trophic lateral sclerosis (ALS), neuropathic pain, and epilepsy.
RNA interference (RNAi) mechanisms have been harnessed to target
the protein transcript and prevent the accumulation of mutant hun-
tingtin protein (HTT) that is the hallmark of HD.144 AAV delivery of
therapeutic microRNAs have been demonstrated to reduce basal
ganglia HTT expression in healthy rhesus macaques and selectively
knock down certain mutant HTT alleles in a mouse and minipig
model of HD.145–147 Another novel therapeutic mechanism utilizing
AAVs that has shown remarkable promise involves delivery of
CRISPR-Cas9 gene-editing systems to selectively suppress mutant
HTT in the striatum.148,149 In these mouse models of HD, CRISPR-
Cas9-mediated disruption of the mutant HTT gene reduced neuronalMolecuinclusions, improved motor deficits, and increased lifespan. Others
have used AAV vector-induced expression of zinc finger proteins to
repress mutant HTT expression.150,151
Similar to HD, RNAi mechanisms and gene-editing systems using
AAV vectors have also been a popular therapeutic strategy for ad-
dressing ALS. A form of familial ALS caused by an intron repeat
expansion in the chromosome 9 open reading frame 72 (C9orf72)
gene, which leads to the accumulation of toxic RNA foci and protein
in affected cells, has been extensively studied.152,153 The feasibility for
a therapeutic microRNA delivered via an AAV5 vector was recently
demonstrated by its ability to reduce C9orf72 expression in both
HEK293T cells and induced pluripotent stem cell-derived neurons
as well as in vivo using a mouse model of ALS.152 Mutations in super-
oxide dismutase-1 (SOD1), which lead to toxic aggregates of mis-
folded protein, are another common cause of familial ALS, and an
alternative to RNAi may be to deliver an AAV that expresses a protein
that prevents this toxic SOD1 misfolding.153 Recently, a study
demonstrated that an AAV delivering macrophage migration inhib-
itory factor (a protein shown to inhibit mutant SOD1 misfolding)
reduced spinal cord levels of misfolded SOD1 and significantly de-
layed disease onset, prolonging overall survival in a mouse model
of overexpressing mutant SOD1.154 Another potential mechanism
for targeting mutant SOD1 was recently demonstrated with a targeted
disruption of mutant SOD1 expression in the spinal cord using the
CRISPR-Cas9 gene-editing system delivered via an AAV vector.155
This reduction in mutant SOD1 was associated with significantly
greater motor neuron survival (50%) and markedly delayed disease
onset in the ALS model.
The mechanisms for AAV-based therapies for neuropathic pain and
epilepsy have been more diverse, likely reflecting the complex, hetero-
geneous underlying mechanisms that contribute to both disease states.
Several studies have investigated the ability of neuropeptide Y, deliv-
ered to the brain via AAVs, to reduce seizure activity in various rodent
models of epilepsy.156–158 A study recently demonstrated that an
AAV1 therapeutic vector could effectively transduce human neuronal
cells to express neuropeptide Y, supporting further preclinical investi-
gation.159 Preclinical studies for neuropathic pain frequently include
using AAVs to deliver genes that will alter the excitability of peripheral
neurons, thereby reducing hyperexcitability, which is thought to un-
derlie the hyperalgesia and allodynia often present in patients with
the disease. For instance, calcium channel-binding domain 3 (CBD3)
blocks N-type voltage-gated calcium channel activity in the spinal
cord and dorsal root ganglion. A recent study demonstrated that
AAV-mediated expression of CBD3was able to decrease pain behavior
in a rat model of neuropathic pain.160 Although more investigation is
needed, these preclinical studies of neurological diseases demonstrate
feasibility and support the potential application of AAV-based gene
therapies in the clinic one day soon.
While considerable progress in AAV-based gene therapies has
occurred in the last two decades, there remains room for improve-
ment. AAVs have been established as safe, well-tolerated viral vectors,lar Therapy: Methods & Clinical Development Vol. 17 June 2020 77
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reducing the production of neutralizing antibodies, and targeting
specific cell populations. In addition to these biological barriers, the
financial burden of gene therapies on manufactures, healthcare sys-
tems, and individual patients will continue to stifle their clinical appli-
cation unless alternative payment strategies are developed and/or
large-scale gene therapy manufacturing methods are significantly
advanced. These biological and financial obstacles must be overcome
if these promising AAV-based gene therapies are expected to become
practical therapeutic strategies in the everyday treatment of disease.
Conclusion
AAVs have been truly transformative for basic neuroscience research,
allowing for great advances in our understanding of brain connectiv-
ity, cellular function (including neurons and glia), and the roles of
specific molecules and cell types in complex animal behaviors. As pre-
clinical studies continue to provide more powerful AAV vectors for
transducing specific cell types in the nervous system and more
advanced methodologies for easier delivery of AAVs to the CNS,
these findings from basic research have increasing translational
potential for the development of novel therapeutics. Indeed, as pre-
sented herein, there is already accumulating evidence that AAV-
based therapies are likely to be successful agents for treating a variety
of neurological diseases. The speed at which advances in AAV-based
neuroscience research tools are progressing suggests that the coming
years will be further filled with exciting new discoveries and the devel-
opment of new treatments that will substantially improve many peo-
ple’s lives.
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